100 Participants Needed

Quercetin for Coronary Artery Disease

(Q-CABG Trial)

ET
MC
Overseen ByMichel Carrier, MD
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking quinolone antibiotics or quercetin supplements.

What evidence supports the effectiveness of the treatment Quercetin for Coronary Artery Disease?

Research suggests that quercetin, a natural compound found in many fruits and vegetables, has antioxidant and anti-inflammatory properties that may help manage conditions like atherosclerosis (a disease where plaque builds up in the arteries). While quercetin significantly increases its levels in the blood, studies have not shown it to directly affect heart disease risk factors in healthy individuals.12345

Is quercetin safe for human use?

Research on flavonoids, including quercetin, suggests they generally have low toxicity in human cell studies, indicating they are likely safe for human use. However, the safety of quercetin specifically for coronary artery disease has not been directly addressed in the provided studies.678910

How is the drug quercetin unique in treating coronary artery disease?

Quercetin is unique because it has antioxidant and anti-inflammatory properties that help protect the heart by improving blood flow, reducing heart rhythm issues, and limiting heart damage during a heart attack. It also helps maintain the integrity of blood vessels, which can prevent blood clots and improve overall heart function.311121314

What is the purpose of this trial?

This trial is testing quercetin, a natural substance found in fruits and vegetables, to see if it can reduce inflammation and slow down aging cells in patients undergoing heart bypass surgery. Patients will take quercetin starting before their surgery and continue for a short period afterward. The study will measure inflammation and cell health through blood samples. Quercetin is known for its antioxidant, anti-inflammatory, and cardio-protective properties.

Research Team

MC

Michel Carrier, MD

Principal Investigator

Montreal Heart Institute

Eligibility Criteria

This trial is for adults who've had a heart attack in the last 30 days or have stable angina, awaiting coronary artery bypass surgery. They must speak French or English and consent to participate. Excluded are those without recent heart attacks, with infections, severe kidney/liver disease, estrogen-dependent tumor history, flavonoid intolerance, or taking certain medications.

Inclusion Criteria

I had a heart attack in the last 30 days or my chest pain is stable.
To be able to give free and enlighten consent
I am hospitalized and waiting for heart bypass surgery.
See 1 more

Exclusion Criteria

I have had breast cancer or another estrogen-dependent tumor before.
You are unable to tolerate flavonoids, niacin, or ascorbic acid.
I am currently taking a quinolone medication.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Pre-surgery Treatment

Participants receive quercetin or placebo starting 2 days before surgery

2 days
1 visit (in-person)

Surgery and Immediate Post-surgery

Participants undergo coronary artery by-pass graft surgery and receive treatment during hospitalization

Up to 10 days
In-patient stay

Follow-up

Participants are monitored for health status and changes post-surgery

8 to 12 weeks
1 visit (in-person)

Treatment Details

Interventions

  • Quercetin
Trial Overview The study examines Quercetin's potential to reduce inflammation and slow cell aging during coronary bypass surgery compared to a placebo. Participants will be randomly assigned to receive either Quercetin or an inactive substance.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: QuercetinActive Control1 Intervention
Patients receiving 500 mg quercetin twice daily
Group II: PlaceboPlacebo Group1 Intervention
Patients receiving placebo twice daily

Quercetin is already approved in United States for the following indications:

🇺🇸
Approved in United States as Quercetin for:
  • Herbal Supplementation
  • Nonbacterial Chronic Prostatitis
  • Interstitial Cystitis

Find a Clinic Near You

Who Is Running the Clinical Trial?

Montreal Heart Institute

Lead Sponsor

Trials
125
Recruited
85,400+

References

Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. [2021]
Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. [2022]
Citrus flavonoids and adhesion molecules: Potential role in the management of atherosclerosis. [2023]
The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis. [2022]
Isoquercitrin Esters with Mono- or Dicarboxylic Acids: Enzymatic Preparation and Properties. [2018]
Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines: relationship between structure and activity. [2019]
The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells. [2022]
Citrus Flavanones Enhance β-Carotene Uptake in Vitro Experiment Using Caco-2 Cell: Structure-Activity Relationship and Molecular Mechanisms. [2019]
Antiproliferative activity of flavonoids on several cancer cell lines. [2022]
Analysis of Citrus Bioflavonoid Content and Dipeptidyl Peptidase-4 Inhibitory Potential of Commercially Available Supplements. [2022]
11.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[The cardioprotective action of quercetin in experimental occlusion and reperfusion of the coronary artery in dogs]. [2013]
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, open label pilot study. [2023]
13.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[The effect of the 5-lipoxygenase inhibitor quercetin on the functional and morphologic manifestations of myocardial lesions in ischemia and reperfusion of the heart]. [2017]
Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security